FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206042302> ?p ?o ?g. }

• W4206042302 endingPage "232" @default.
• W4206042302 startingPage "219" @default.
• W4206042302 abstract "Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study was to evaluate the efficacy of lenvatinib in a multi-center cohort (ELEVATOR) from Germany and Austria. Methods A retrospective data analysis of 205 patients treated with first-line systemic lenvatinib at 14 different sites was conducted. Overall survival, progression free survival, overall response rate and adverse event rates were assessed and analyzed. Results Patients receiving lenvatinib in the real-world setting reached a median overall survival of 12.8 months, which was comparable to the results reported from the REFLECT study. Median overall survival (mOS) and progression free survival (mPFS) was superior in those patients who met the inclusion criteria of the REFLECT study compared to patients who failed to meet the inclusion criteria (mOS 15.6 vs 10.2 months, HR 0.55, 95% CI 0.38-0.81, p=0.002; mPFS 8.1 vs 4.8 months HR 0.65, 95% CI 0.46-0.91, p=0.0015). For patients with an impaired liver function according to the Albumin-Bilirubin (ALBI) grade, or reduced ECOG performance status ≥2, survival was significantly shorter compared to patients with sustained liver function (ALBI grade 1) and good performance status (ECOG performance status 0), respectively (HR 1.69, 95% CI 1.07-2.66, p=0.023; HR 2.25, 95% CI 1.19-4.23, p=0.012). Additionally, macrovascular invasion (HR 1.55, 95% CI 1.02-2.37, p=0.041) and an AFP ≥200 ng/mL (HR 1.56, 95% CI 1.03-2.34, p=0.034) were confirmed as independent negative prognostic factors in our cohort of patients with advanced HCC. Conclusion Overall, our data confirm the efficacy of lenvatinib as first-line treatment and did not reveal new or unexpected side effects in a large retrospective Caucasian real-world cohort, supporting the use of lenvatinib as meaningful alternative for patients that cannot be treated with IO-based combinations in first-line HCC." @default.
• W4206042302 created "2022-01-26" @default.
• W4206042302 creator A5004228804 @default.
• W4206042302 creator A5005113840 @default.
• W4206042302 creator A5005730211 @default.
• W4206042302 creator A5009023308 @default.
• W4206042302 creator A5019331407 @default.
• W4206042302 creator A5022604215 @default.
• W4206042302 creator A5023227183 @default.
• W4206042302 creator A5024115698 @default.
• W4206042302 creator A5029158617 @default.
• W4206042302 creator A5033337416 @default.
• W4206042302 creator A5033769350 @default.
• W4206042302 creator A5035002011 @default.
• W4206042302 creator A5037309830 @default.
• W4206042302 creator A5039994927 @default.
• W4206042302 creator A5047311905 @default.
• W4206042302 creator A5050082655 @default.
• W4206042302 creator A5062083405 @default.
• W4206042302 creator A5072835159 @default.
• W4206042302 creator A5074135677 @default.
• W4206042302 creator A5077695312 @default.
• W4206042302 creator A5079350752 @default.
• W4206042302 creator A5079645039 @default.
• W4206042302 creator A5080568956 @default.
• W4206042302 creator A5081080307 @default.
• W4206042302 creator A5085805107 @default.
• W4206042302 creator A5086026527 @default.
• W4206042302 creator A5087125537 @default.
• W4206042302 creator A5089874345 @default.
• W4206042302 creator A5090224526 @default.
• W4206042302 date "2022-01-01" @default.
• W4206042302 modified "2023-10-18" @default.
• W4206042302 title "Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study" @default.
• W4206042302 cites W1757407923 @default.
• W4206042302 cites W1971837077 @default.
• W4206042302 cites W2050244237 @default.
• W4206042302 cites W2076668534 @default.
• W4206042302 cites W2094109552 @default.
• W4206042302 cites W2141444851 @default.
• W4206042302 cites W2560499218 @default.
• W4206042302 cites W2581205085 @default.
• W4206042302 cites W2727497670 @default.
• W4206042302 cites W2787358630 @default.
• W4206042302 cites W2790326980 @default.
• W4206042302 cites W2890595557 @default.
• W4206042302 cites W2895926103 @default.
• W4206042302 cites W2908573150 @default.
• W4206042302 cites W2945004896 @default.
• W4206042302 cites W2980236331 @default.
• W4206042302 cites W2995953853 @default.
• W4206042302 cites W3000401463 @default.
• W4206042302 cites W3006994451 @default.
• W4206042302 cites W3025022288 @default.
• W4206042302 cites W3035732877 @default.
• W4206042302 cites W3045387409 @default.
• W4206042302 cites W3045557449 @default.
• W4206042302 cites W3080424252 @default.
• W4206042302 cites W3094496272 @default.
• W4206042302 cites W3121032265 @default.
• W4206042302 cites W3127211083 @default.
• W4206042302 cites W3128646645 @default.
• W4206042302 cites W3157139293 @default.
• W4206042302 cites W3158188532 @default.
• W4206042302 cites W3165018140 @default.
• W4206042302 cites W4242769447 @default.
• W4206042302 doi "https://doi.org/10.1159/000521746" @default.
• W4206042302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35949288" @default.
• W4206042302 hasPublicationYear "2022" @default.
• W4206042302 type Work @default.
• W4206042302 citedByCount "16" @default.
• W4206042302 countsByYear W42060423022022 @default.
• W4206042302 countsByYear W42060423022023 @default.
• W4206042302 crossrefType "journal-article" @default.
• W4206042302 hasAuthorship W4206042302A5004228804 @default.
• W4206042302 hasAuthorship W4206042302A5005113840 @default.
• W4206042302 hasAuthorship W4206042302A5005730211 @default.
• W4206042302 hasAuthorship W4206042302A5009023308 @default.
• W4206042302 hasAuthorship W4206042302A5019331407 @default.
• W4206042302 hasAuthorship W4206042302A5022604215 @default.
• W4206042302 hasAuthorship W4206042302A5023227183 @default.
• W4206042302 hasAuthorship W4206042302A5024115698 @default.
• W4206042302 hasAuthorship W4206042302A5029158617 @default.
• W4206042302 hasAuthorship W4206042302A5033337416 @default.
• W4206042302 hasAuthorship W4206042302A5033769350 @default.
• W4206042302 hasAuthorship W4206042302A5035002011 @default.
• W4206042302 hasAuthorship W4206042302A5037309830 @default.
• W4206042302 hasAuthorship W4206042302A5039994927 @default.
• W4206042302 hasAuthorship W4206042302A5047311905 @default.
• W4206042302 hasAuthorship W4206042302A5050082655 @default.
• W4206042302 hasAuthorship W4206042302A5062083405 @default.
• W4206042302 hasAuthorship W4206042302A5072835159 @default.
• W4206042302 hasAuthorship W4206042302A5074135677 @default.
• W4206042302 hasAuthorship W4206042302A5077695312 @default.
• W4206042302 hasAuthorship W4206042302A5079350752 @default.
• W4206042302 hasAuthorship W4206042302A5079645039 @default.
• W4206042302 hasAuthorship W4206042302A5080568956 @default.
• W4206042302 hasAuthorship W4206042302A5081080307 @default.

• next